# Veryan Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veryan-holdings

- Industry: Medical Devices & Equipment
- Headquarters: Horsham, UK
- Website: www.veryanmed.com
- Total disclosed funding: $40M
- Latest round: Series B (Jan 14, 2015)
- Investors on record: 8

## About

Based in the UK, Veryan Holdings Ltd. specializes in developing and manufacturing innovative vascular devices, primarily focusing on the BioMimics-3D Vascular Stent System for enhanced patient outcomes in vascular health.Veryan Holdings Ltd. designs and manufactures advanced vascular devices, particularly known for the BioMimics-3D Vascular Stent System. Founded in 2003, the company is headquartered in Horsham, UK. In December 2018, Veryan was acquired by Otsuka Medical Devices Co., Ltd., although the financial terms were not disclosed. The company has engaged in 7 deals, with its most recent investment round being Series B, raising GBP 16.000 mn, led by Touchstone Innovations, with total funding amounting to GBP 16.000 mn and a current valuation of GBP 29.095 mn.Veryan Medical specializes in the design and manufacture of innovative vascular devices, prominently featuring the BioMimics-3D Vascular Stent System. This flagship product is characterized by its unique 3D helical geometry, which facilitates a gentle helical shape in the stented artery, enhancing vascular flow dynamics. The BioMimics-3D stent is utilized primarily in the treatment of peripheral artery disease, offering a biocompatible solution that aims to improve patient outcomes in comparison to traditional drug-eluting stents. The company markets its products to healthcare providers, including hospitals and specialized clinics, focusing on markets in Europe and North America, where it adheres to regulatory standards set forth by FDA and CE Mark approvals. These products cater to a diverse clientele, including interventional cardiologists and vascular surgeons, who utilize these advanced stenting solutions in a variety of clinical settings.In the most recent fiscal year, 2023, Veryan Medical generated revenue of GBP 14,548,632.40, with an EBITDA of GBP -6,243,865.20. The revenue model is anchored in direct sales of its medical devices to healthcare institutions, primarily conducted through B2B channels. Their sales strategy includes establishing partnerships with healthcare facilities to ensure consistent supply and support for their products, facilitating a streamlined purchasing process that meets the needs of healthcare providers and enhances patient care outcomes.Veryan Holdings Ltd. plans to leverage its recent Series B funding to advance commercialization and drive the development of innovative products. The company is focused on expanding into new markets, particularly targeting regions in Europe and North America, with specific product launches being scheduled in the upcoming years. The acquisition by Otsuka Medical Devices Co., Ltd. is expected to support these growth initiatives, enhancing Veryan’s ability to innovate and meet the evolving demands of the vascular health sector.

## Funding rounds

- Series B, Jan 14, 2015, $24M — Seroba, Touchstone Innovations, Seven Mile Capital Partners, Invesco Asset Management
- Series B, Apr 6, 2010, $5.4M — Seroba, Oxford Capital Partners, NESTA Investments, Imperial Innovations
- Series A, Mar 11, 2010 — Seroba, Oxford Capital Partners, NESTA Investments, Imperial Innovations
- Series B, May 11, 2007, $6.1M — Oxford Capital Partners, NESTA Investments, Touchstone Innovations
- Series A, Jan 10, 2006, $4.5M — Oxford Capital Partners, NESTA Investments, Touchstone Innovations, NPI Ventures

## Investors

- Oxford Capital Partners (https://capitalatlas.ai/funds/oxford-capital-partners) — Series A, Series B
- NESTA Investments — Series A, Series B
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A, Series B
- NPI Ventures — Series A
- Seroba (https://capitalatlas.ai/funds/seroba) — Series A, Series B
- Imperial Innovations — Series A, Series B
- Seven Mile Capital Partners (https://capitalatlas.ai/funds/seven-mile-capital-partners) — Series B
- Invesco Asset Management — Series B